Last reviewed · How we verify
Dorzolamide Hcl 2% Oph Soln
Dorzolamide Hcl 2% Oph Soln is a Small molecule drug developed by University of the Incarnate Word. It is currently FDA-approved. Also known as: Azopt.
At a glance
| Generic name | Dorzolamide Hcl 2% Oph Soln |
|---|---|
| Also known as | Azopt |
| Sponsor | University of the Incarnate Word |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dorzolamide Hcl 2% Oph Soln CI brief — competitive landscape report
- Dorzolamide Hcl 2% Oph Soln updates RSS · CI watch RSS
- University of the Incarnate Word portfolio CI
Frequently asked questions about Dorzolamide Hcl 2% Oph Soln
What is Dorzolamide Hcl 2% Oph Soln?
Dorzolamide Hcl 2% Oph Soln is a Small molecule drug developed by University of the Incarnate Word.
Who makes Dorzolamide Hcl 2% Oph Soln?
Dorzolamide Hcl 2% Oph Soln is developed and marketed by University of the Incarnate Word (see full University of the Incarnate Word pipeline at /company/university-of-the-incarnate-word).
Is Dorzolamide Hcl 2% Oph Soln also known as anything else?
Dorzolamide Hcl 2% Oph Soln is also known as Azopt.
What development phase is Dorzolamide Hcl 2% Oph Soln in?
Dorzolamide Hcl 2% Oph Soln is FDA-approved (marketed).
Related
- Manufacturer: University of the Incarnate Word — full pipeline
- Also known as: Azopt